Boston Scientific EBITDA 2010-2024 | BSX
Boston Scientific annual and quarterly EBITDA history from 2010 to 2024. EBITDA can be defined as earnings before interest, taxes, depreciation and amortization.
- Boston Scientific EBITDA for the quarter ending December 31, 2024 was $1.137B, a 26.47% increase year-over-year.
- Boston Scientific EBITDA for the twelve months ending December 31, 2024 was $4.260B, a 18.43% increase year-over-year.
- Boston Scientific 2024 annual EBITDA was $4.26B, a 18.43% increase from 2023.
- Boston Scientific 2023 annual EBITDA was $3.597B, a 23.4% increase from 2022.
- Boston Scientific 2022 annual EBITDA was $2.915B, a 9.55% increase from 2021.
| Boston Scientific Annual EBITDA (Millions of US $) |
|
|---|---|
| 2024 | $4,260 |
| 2023 | $3,597 |
| 2022 | $2,915 |
| 2021 | $2,661 |
| 2020 | $1,577 |
| 2019 | $2,633 |
| 2018 | $2,435 |
| 2017 | $2,133 |
| 2016 | $1,273 |
| 2015 | $505 |
| 2014 | $619 |
| 2013 | $1,285 |
| 2012 | $1,307 |
| 2011 | $2,339 |
| 2010 | $2,042 |
| 2009 | $-48 |
| Boston Scientific Quarterly EBITDA (Millions of US $) |
|
|---|---|
| 2024-12-31 | $1,137 |
| 2024-09-30 | $1,039 |
| 2024-06-30 | $1,107 |
| 2024-03-31 | $977 |
| 2023-12-31 | $899 |
| 2023-09-30 | $993 |
| 2023-06-30 | $869 |
| 2023-03-31 | $836 |
| 2022-12-31 | $695 |
| 2022-09-30 | $767 |
| 2022-06-30 | $696 |
| 2022-03-31 | $757 |
| 2021-12-31 | $667 |
| 2021-09-30 | $787 |
| 2021-06-30 | $570 |
| 2021-03-31 | $637 |
| 2020-12-31 | $421 |
| 2020-09-30 | $265 |
| 2020-06-30 | $284 |
| 2020-03-31 | $607 |
| 2019-12-31 | $209 |
| 2019-09-30 | $383 |
| 2019-06-30 | $384 |
| 2019-03-31 | $541 |
| 2018-12-31 | $318 |
| 2018-09-30 | $389 |
| 2018-06-30 | $391 |
| 2018-03-31 | $408 |
| 2017-12-31 | $319 |
| 2017-09-30 | $377 |
| 2017-06-30 | $225 |
| 2017-03-31 | $364 |
| 2016-12-31 | $140 |
| 2016-09-30 | $348 |
| 2016-06-30 | $-334 |
| 2016-03-31 | $293 |
| 2015-12-31 | $-227 |
| 2015-09-30 | $-299 |
| 2015-06-30 | $219 |
| 2015-03-31 | $24 |
| 2014-12-31 | $-493 |
| 2014-09-30 | $64 |
| 2014-06-30 | $-69 |
| 2014-03-31 | $197 |
| 2013-12-31 | $127 |
| 2013-09-30 | $103 |
| 2013-06-30 | $220 |
| 2013-03-31 | $-330 |
| 2012-12-31 | $117 |
| 2012-09-30 | $-594 |
| 2012-06-30 | $-3,587 |
| 2012-03-31 | $196 |
| 2011-12-31 | $171 |
| 2011-09-30 | $174 |
| 2011-06-30 | $237 |
| 2011-03-31 | $322 |
| 2010-12-31 | $348 |
| 2010-09-30 | $251 |
| 2010-06-30 | $231 |
| 2010-03-31 | $-1,486 |
| 2009-12-31 | $-1,231 |
| 2009-09-30 | $51 |
| 2009-06-30 | $275 |
| 2009-03-31 | $11 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Products Manufacturing | $154.056B | $16.747B |
| Boston Scientific Corporation manufactures medical devices and products used in various interventional medical specialties worldwide. The company has adopted the organic as well as inorganic routes for success. Boston Scientific currently has 3 global reportable segments - Cardiovascular, Rhythm and Neuro and MedSurg. While Cardiovascular includes Interventional Cardiology and Peripheral Interventions, Rhythm and Neuro comprises Cardiac Rhythm Management, Electrophysiology and Neuromodulation. The MedSurg group comprises 2 sub segments, viz. Endoscopy, Urology and Pelvic Health. Boston Scientific markets a broad portfolio of internally-developed and self-manufactured drug eluting stents including the Promus PREMIER, Promus Element and Promus Element Plus everolimus-eluting stents. Within the CRM segment, the company deals with implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Abbott Laboratories (ABT) | United States | $234.047B | 28.90 |
| Stryker (SYK) | United States | $148.022B | 31.82 |
| EssilorLuxottica (ESLOY) | France | $137.298B | 0.00 |
| Medtronic (MDT) | Ireland | $115.624B | 16.89 |
| Lonza Group Ag (LZAGY) | Switzerland | $46.792B | 0.00 |
| Haleon (HLN) | United Kingdom | $45.950B | 29.85 |
| GE HealthCare Technologies (GEHC) | United States | $41.418B | 20.17 |
| Agilent Technologies (A) | United States | $38.594B | 25.57 |
| ResMed (RMD) | United States | $33.728B | 25.98 |
| Terumo (TRUMY) | Japan | $25.984B | 36.95 |
| Koninklijke Philips (PHG) | Netherlands | $24.420B | 17.44 |
| Zimmer Biomet Holdings (ZBH) | United States | $21.098B | 13.25 |
| Insulet (PODD) | United States | $19.908B | 85.13 |
| Baxter (BAX) | United States | $17.948B | 12.94 |
| Smith & Nephew SNATS (SNN) | United Kingdom | $11.490B | 0.00 |
| Sunny Optical Technology (SNPTF) | China | $11.331B | 0.00 |
| BellRing Brands (BRBR) | United States | $9.348B | 35.03 |
| Demant (WILYY) | Denmark | $8.092B | 0.00 |
| Bio-Rad Laboratories (BIO) | United States | $7.847B | 27.17 |
| Lantheus Holdings (LNTH) | United States | $5.489B | 12.75 |
| Prestige Consumer Healthcare (PBH) | United States | $4.215B | 20.11 |
| ICU Medical (ICUI) | United States | $3.924B | 37.35 |
| Envista Holdings (NVST) | United States | $3.683B | 29.30 |
| Perrigo (PRGO) | Ireland | $3.443B | 10.14 |
| Haemonetics (HAE) | United States | $3.312B | 15.58 |
| Shandong Weigao Medical Polymer (SHWGF) | China | $2.989B | 0.00 |
| GN Store Nord (GNNDY) | Denmark | $2.850B | 19.20 |
| QuidelOrtho (QDEL) | United States | $2.822B | 23.71 |
| LeMaitre Vascular (LMAT) | United States | $2.294B | 55.75 |
| Neogen (NEOG) | United States | $2.261B | 26.05 |
| AtriCure (ATRC) | United States | $1.916B | 0.00 |
| Green Thumb Industries (GTBIF) | United States | $1.494B | 26.06 |
| InMode (INMD) | Israel | $1.330B | 11.12 |
| BioLife Solutions (BLFS) | United States | $1.193B | 0.00 |
| AdaptHealth (AHCO) | United States | $1.150B | 8.22 |
| Maravai LifeSciences Holdings (MRVI) | United States | $1.013B | 0.00 |
| Curaleaf Holdings (CURLF) | Canada | $0.920B | 0.00 |
| CeriBell (CBLL) | United States | $0.911B | 0.00 |
| Phibro Animal Health (PAHC) | United States | $0.896B | 13.74 |
| Evolus (EOLS) | United States | $0.893B | 0.00 |
| Capricor Therapeutics (CAPR) | United States | $0.657B | 0.00 |
| Valneva SE (VALN) | France | $0.635B | 0.00 |
| VAREX IMAGING (VREX) | United States | $0.538B | 23.32 |
| Omeros (OMER) | United States | $0.503B | 0.00 |
| Surmodics (SRDX) | United States | $0.501B | 0.00 |
| Owens & Minor (OMI) | United States | $0.493B | 3.85 |
| SNDL (SNDL) | Canada | $0.439B | 0.00 |
| Cresco Labs (CRLBF) | United States | $0.432B | 0.00 |
| ZimVie (ZIMV) | United States | $0.368B | 30.98 |
| SEMPERIT AG HLD (SEIGY) | Austria | $0.349B | 0.00 |
| Verano Holdings (VRNOF) | United States | $0.349B | 0.00 |
| Quanterix (QTRX) | United States | $0.311B | 0.00 |
| Sanara MedTech (SMTI) | United States | $0.309B | 0.00 |
| Aurora Cannabis (ACB) | Canada | $0.308B | 56.10 |
| Cerus (CERS) | United States | $0.305B | 0.00 |
| Viemed Healthcare (VMD) | United States | $0.300B | 28.52 |
| OraSure Technologies (OSUR) | United States | $0.298B | 19.95 |
| Biote (BTMD) | United States | $0.252B | 5.52 |
| Canopy Growth (CGC) | Canada | $0.252B | 0.00 |
| Zynex (ZYXI) | United States | $0.234B | 49.07 |
| Sanuwave Health (SNWV) | United States | $0.231B | 3.24 |
| High Tide (HITI) | Canada | $0.205B | 0.00 |
| Utah Medical Products (UTMD) | United States | $0.204B | 15.21 |
| Brainsway (BWAY) | Israel | $0.184B | 97.80 |
| TriSalus Life Sciences (TLSI) | United States | $0.168B | 0.00 |
| MacroGenics (MGNX) | United States | $0.166B | 0.00 |
| TerrAscend (TSNDF) | Canada | $0.164B | 0.00 |
| Organigram Holdings (OGI) | Canada | $0.154B | 0.00 |
| FitLife Brands (FTLF) | United States | $0.137B | 17.17 |
| Jin Medical (ZJYL) | China | $0.114B | 0.00 |
| Quipt Home Medical (QIPT) | United States | $0.114B | 0.00 |
| Fonar (FONR) | United States | $0.092B | 12.92 |
| Oramed Pharmaceuticals (ORMP) | United States | $0.087B | 0.00 |
| Veru (VERU) | United States | $0.083B | 0.00 |
| InterCure (INCR) | Israel | $0.076B | 0.00 |
| Jushi Holdings (JUSHF) | United States | $0.069B | 0.00 |
| Exagen (XGN) | United States | $0.063B | 0.00 |
| Cytosorbents (CTSO) | United States | $0.060B | 0.00 |
| Rockwell Medical (RMTI) | United States | $0.057B | 29.17 |
| Apyx Medical (APYX) | United States | $0.054B | 0.00 |
| Hongchang (HCIL) | China | $0.051B | 0.00 |
| United-Guardian (UG) | United States | $0.046B | 13.24 |
| ImmuCell (ICCC) | United States | $0.045B | 0.00 |
| Modular Medical (MODD) | United States | $0.042B | 0.00 |
| INLIF (INLF) | $0.032B | 0.00 | |
| Safety Shot (SHOT) | United States | $0.028B | 0.00 |
| Nephros (NEPH) | United States | $0.017B | 0.00 |
| Trinity Biotech (TRIB) | Ireland | $0.015B | 0.00 |
| Cellectar Biosciences (CLRB) | United States | $0.014B | 0.00 |
| Flora Growth (FLGC) | United States | $0.013B | 0.00 |
| Innovative Eyewear (LUCY) | United States | $0.010B | 0.00 |
| NeuroMetrix (NURO) | United States | $0.009B | 0.00 |
| Meihua Medical Technologies (MHUA) | China | $0.009B | 0.00 |
| Allurion Technologies (ALUR) | United States | $0.009B | 0.00 |
| Agape ATP (ATPC) | $0.006B | 0.00 | |
| IM Cannabis (IMCC) | Canada | $0.005B | 0.00 |
| GlucoTrack (GCTK) | United States | $0.004B | 0.00 |
| Senestech (SNES) | United States | $0.003B | 0.00 |
| Akanda (AKAN) | United Kingdom | $0.002B | 0.00 |
| Sharps Technology (STSS) | United States | $0.002B | 0.00 |
| InVivo Therapeutics Holdings (NVIVQ) | United States | $0.000B | 0.00 |